News

Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America ...
Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...
Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...
Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...
Zoetis (ZTS) stock is in focus after reporting earnings. Zoetis CFO Wetteny Joseph joins Market Catalysts to discuss the ...
Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...
Zoetis Q2 EPS rose to $1.76 vs. $1.61 estimate; revenue hit $2.50 billion, beating $2.41 billion forecast. Full-year EPS guidance raised to $6.30–$6.40 from $6.20–$6.30. Get ahead of next week ...
Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...
Shares of Zoetis Inc. ZTS rallied 1.09% to $147.38 Friday, on what proved to be an all-around dismal trading session for the ...
Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.
Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.